Cyfuse Biomedical KK

Cyfuse Biomedical KK Net Margin

The Net Profit Margin of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is -330.67 %. In the previous year, Net Profit Margin was -1,602.02 % — a change of -79.36% (higher).

Net Margin

-330.67 %

YoY

-79.36%

Last updated:

Net Profit Margin of Cyfuse Biomedical KK is 2025 -330.67 % . Net Profit Margin of Cyfuse Biomedical KK was 2024 -1,602.02 % . It decreases by -79.36% higher compared to the previous year.

For Cyfuse Biomedical KK, the net margin of -330.7% is down versus 20.2% a few years ago.

The Cyfuse Biomedical KK Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2020
-239.66 JPY
Jan 1, 2021
20.18 JPY
Jan 1, 2022
-126.57 JPY
Jan 1, 2023
-964.15 JPY
Jan 1, 2024
-1,602.02 JPY
Jan 1, 2025
-330.67 JPY
The Cyfuse Biomedical KK Net Margin history
YEARNet MarginYoY
-330.67 %-79.36%
-1,602.02 %+66.16%
-964.15 %+661.77%
-126.57 %-727.27%
20.18 %-108.42%
-239.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

Net Profit Margin of Cyfuse Biomedical KK is -330.67 % in 2025.

Net Profit Margin of Cyfuse Biomedical KK changed from -1,602.02 % to -330.67 %, representing a -79.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Cyfuse Biomedical KK with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Cyfuse Biomedical KK

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Cyfuse Biomedical KK